AIDS drugs given to pregnant women block 99 percent of HIV transmission to breastfed babies

June 16, 2010

Boston, MA -- An international clinical trial led by researchers at the Harvard School of Public Health (HSPH) has found that AIDS-fighting antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana, Africa, prevented 99% of the mothers from transmitting the human immunodeficiency virus (HIV) to their infants.

"This is the lowest rate of mother-to-child transmission recorded in a study from Africa, or among breastfeeding infants," said lead author Roger Shapiro, Associate Professor of Medicine at Harvard Medical School and Harvard School of Public Health. The mother-to-child transmission rate in the study was 1.1% when the infants were breastfed to age 6 months. "Previous interventions using shorter or less comprehensive drug treatment regimens have been unable to get rates below 5%, and without any intervention, the infection rate would be at least 25% by 6 months," said Shapiro.

The study was also the first randomized clinical trial to compare highly active antiretroviral therapy (HAART) regimens used during pregnancy or breastfeeding.

The article will appear in the June 17 edition of The New England Journal of Medicine. It is accompanied by an editorial by Dr. Lynne Mofenson of the National Institutes of Heath, who notes the important role for maternal HAART use during pregnancy and breastfeeding, particularly among women who also qualify for HAART as treatment for their own health. Dr. Mofenson states, "The intervention that would have the most substantial impact on HIV-1-related maternal deaths and perinatal infections throughout the world is the initiation of lifelong antiretroviral therapy in pregnant and lactating women infected with HIV-1 who meet the treatment criteria."

Breastfeeding is normally the best way to feed an infant and is one of the most critical factors for improving child survival in developing nations. A woman infected with HIV, however, can transmit the virus to her child during breastfeeding, as well as during pregnancy, labor and delivery.

The research was part of the Mma Bana Study (meaning "mother of the baby" in Setswana) conducted in southern Botswana as a collaboration between HSPH and the Botswana government (the Botswana-Harvard AIDS Institute Partnership) to improve health for women and children. Established in 1996, the partnership is a collaborative research and training initiative between the Government of Botswana and the Harvard School of Public Health AIDS Initiative.

The use of HAART to prevent mother-to-child HIV transmission is one of the most successful public health interventions to prevent the transmission of AIDS in pregnancy. Little has been known, however, about its promise for halting HIV transmission from mother to infant through breastfeeding in areas of the world where formula feeding is neither safe nor feasible, including most of sub-Saharan Africa.

The study compared the suppression of the mother's HIV virus at delivery and throughout breastfeeding among women assigned to receive one of three treatment regimens. Overall, 730 HIV-infected pregnant women were included in the study and most started HAART early in the third trimester of pregnancy. Almost all women achieved viral suppression by delivery, and their virus remained undetectable throughout breastfeeding. All three HAART regimens consisted of commonly used antiretroviral combinations with three active drugs. Similar results were found for all treatment groups, including 560 women who were randomized to receive either zidovudine, lamivudine, and abacavir (co-formulated as Trizivir) or zidovudine, lamivudine, lopinivir/ritonavir (Kaletra/Combivir), and 170 sicker women who qualified for treatment for their own health and received zidovudine, lamivudine, and nevirapine (Nevirapine/Combivir) provided by the Botswana government.

All HAART regimens used in the study were found to be highly effective at suppressing the HIV virus, said the authors. They also found the HAART regimens used in the study were safe and generally well-tolerated.

"Until now, HIV-infected mothers in Africa were faced with a choice between breastfeeding and a high risk of infecting their children with HIV, or using formula and risking high infant morbidity and mortality from other diseases associated with not breastfeeding. This study provides a more satisfactory solution," said senior author Max Essex, Mary Woodard Lasker Professor of Health Sciences and chair of the Harvard School of Public Health AIDS Initiative.

The rates of infection with HIV in southern Africa are 3 to 5 times higher than in the rest of sub-Saharan Africa and more than 100 times higher than in the rest of the world. This discrepancy is much greater for women and children. While about 90% of the AIDS patients in the U.S. or Europe receive effective treatment, a much smaller percentage of patients in Africa receive adequate treatment. Children who are HIV infected are much less likely to be in treatment programs, and are usually destined to die of HIV/AIDS at a young age. This makes it even more critical that effective measures are available to prevent them from becoming infected.

The Mma Bana Study findings already have influenced WHO guidelines on the use of HAART to prevent mother-to-child HIV transmission. For the first time, WHO recently recommended that all HIV-infected mothers or their infants take antiretroviral drugs while breastfeeding to prevent HIV transmission. The Botswana government is preparing to roll out a program to provide HAART to all pregnant women with HIV, said Shapiro. Other countries are considering doing the same.

The research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The Fogarty International Center supported several trainees involved in this study. Other Boston institutions participating in the study included Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, and Massachusetts General Hospital.

"Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana," Roger Shapiro, Michael Hughes, Anthony Ogwu, Doug Kitch, Shahin Lockman, Claire Moffat, Joseph Makhema, Sikhulile Moyo, Ibou Thior, Kenneth McIntosh, Erik van Widenfelt, Jean Leidner, Kathleen Powis, Aida Asmelash, Esther Tumbare, Sheryl Zwerski, Usha Sharma, Edward Handelsman, Kinuthia Mburu, Oluwemimo Jayeoba, Evans Moko, Sajini Souda, Edmund Lubega, Maida Akhtar, Carolyn Wester, Wendy Snowden, Marisol Martinez-Tristani, Loeto Mazhani, Max Essex, NEJM, Vol. 362, No. 24, June 17, 2010.
-end-
Visit the HSPH website for the latest news, press releases and multimedia offerings.

For more information:
Todd Datz
617.998.8819
tdatz@hsph.harvard.edu

Harvard School of Public Health (http://www.hsph.harvard.edu ) is dedicated to advancing the public's health through learning, discovery, and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit: http://www.hsph.harvard.edu

Harvard T.H. Chan School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.